InnoCan Pharma (HAM:IP40) LT-Debt-to-Total-Asset: 0.09 (As of Mar. 2026)

What is InnoCan Pharma LT-Debt-to-Total-Asset?

InnoCan Pharma HAM:IP40 -13.50% 59 LT-Debt-to-Total-Asset is 0.09 as of Mar. 2026. GuruFocus rates HAM:IP40 with a GF Score™ of 59/100 and a GF Value™ of €9.62 (Possible Value Trap). The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. InnoCan Pharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.09.

InnoCan Pharma's long-term debt to total assets ratio declined from Mar. 2025 (0.12) to Mar. 2026 (0.09). It may suggest that InnoCan Pharma is progressively becoming less dependent on debt to grow their business.

InnoCan Pharma (HAM:IP40) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

InnoCan Pharma LT-Debt-to-Total-Asset Related Terms

InnoCan Pharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma LT-Debt-to-Total-Asset Chart

InnoCan Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.09

InnoCan Pharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.12	0.13	0.14	0.09	0.09

59GF Score

InnoCan Pharma Corp HAM:IP40

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

InnoCan Pharma LT-Debt-to-Total-Asset Calculation

InnoCan Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0.794	/	8.986
	=	0.09

InnoCan Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0.836	/	9.381
	=	0.09

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.09 mean?

InnoCan Pharma (HAM:IP40) has a LT-Debt-to-Total-Asset of 0.09 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on InnoCan Pharma and its competitors.

Is InnoCan Pharma's LT-Debt-to-Total-Asset too high?

InnoCan Pharma's current LT-Debt-to-Total-Asset is 0.09. Overall, InnoCan Pharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does InnoCan Pharma's LT-Debt-to-Total-Asset compare to PG and CL?

InnoCan Pharma's LT-Debt-to-Total-Asset of 0.09 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Consumer Packaged Goods company?

A good LT-Debt-to-Total-Asset depends on the Consumer Packaged Goods industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on InnoCan Pharma and its competitors. InnoCan Pharma's current LT-Debt-to-Total-Asset is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is InnoCan Pharma stock overvalued right now?

Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.62, compared to a current price of €1.41 — trading 85.3% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.09. InnoCan Pharma's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current LT-Debt-to-Total-Asset is 0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.41 is trading 85.3% below its estimated GF Value™ of €9.62. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for HAM:IP40:

LT-Debt-to-Total-Asset: 0.09
GF Value™: €9.62 vs. price of €1.41 (85.3% below fair value)
GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCan Pharma Business Description

Industry Consumer Defensive Consumer Packaged Goods

Comparable Companies XCNQ:CGII XCNQ:ZRO PG XPAR:OR LSE:ULVR CL BOM:500696 LSE:RKT KVUE KMB XTER:HEN3 EL CHD OSTO:ESSITY B XTER:BEI TSE:4452 CLX BOM:531642 BOM:532424 XMAD:PUIG

Other Exchanges INNPF:USA INNO:Canada

Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7

Website https://www.innocanpharma.com

InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.

59GF Score

Get the complete analysis for HAM:IP40

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.41

Price

€9.62

GF Value

View HAM:IP40 Analysis

See LT-Debt-to-Total-Asset data for all stocks →